Abstract

It is an exciting time for those of us treating patients with severe asthma. We now have more effective ways of assessing patients, monitoring adherence, and defining airway inflammation [1–5]. Current trials should inform on the role of biomarkers in determining treatment response [6], as we move away from a one-size-fits-all approach with oral prednisolone as the best alternative available. We can now select patients for intervention with biologics.